{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:12:18Z","timestamp":1756462338211,"version":"3.44.0"},"reference-count":22,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:p>In the UK, diabetes mellitus affects around 3 million people, of whom over 90% have type 2 diabetes.<jats:sup>1<\/jats:sup> Aims of treatment include minimising long-term complications (e.g. cardiovascular disease, blindness, chronic kidney disease, premature mortality) and avoiding unwanted effects of treatment (e.g. severe hypoglycaemia, weight gain).<jats:sup>2<\/jats:sup> Management of diabetes includes patient support and education; addressing symptoms; lifestyle modification; targeting associated risk factors for cardiovascular disease; and surveillance for, and management of, complications including treatment-related hypoglycaemia.<jats:sup>2<\/jats:sup> \u25bcDapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.<jats:sup>3<\/jats:sup> It is licensed in the UK in adults with type 2 diabetes as monotherapy when diet and exercise alone do not provide adequate glycaemic control and who are unable to tolerate metformin; or, as add-on therapy, with other glucose-lowering agents including insulin, when these, with diet and exercise, do not provide adequate glycaemic control.<jats:sup>3<\/jats:sup> The company's advertising materials claim that dapagliflozin provides a \u201cnovel method of controlling excess glucose\u201d with \u201csecondary benefit of weight loss\u201d. Here, we review the evidence for the use of dapagliflozin in the management of type 2 diabetes mellitus.<\/jats:p>","DOI":"10.1136\/dtb.2013.9.0205","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T03:49:42Z","timestamp":1378957782000},"page":"105-108","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["\u25bcDapagliflozin (Forxiga) for type 2 diabetes?"],"prefix":"10.1136","volume":"51","member":"239","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"key":"2025082722090399000_51.9.105.1","unstructured":"Diabetes UK , 2013. Diabetes prevalence 2012 [online]. Available: http:\/\/www.diabetes.org.uk\/About_us\/What-we-say\/Statistics\/Diabetes-prevalence-2012\/ [Accessed 21 August 2013]."},{"key":"2025082722090399000_51.9.105.2","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2013.4.0172"},{"key":"2025082722090399000_51.9.105.3","unstructured":"Forxiga 5mg & 10mg film coated tablets. Summary of product characteristics, EU. Bristol Myers Squibb-AstraZeneca EEIG, April 2013."},{"key":"2025082722090399000_51.9.105.4","unstructured":"Joint Formulary Committee. British National Formulary. Edition 65 March\u2014September 2013. London: BMJ Group and Pharmaceutical Press, March 2013."},{"key":"2025082722090399000_51.9.105.5","unstructured":"European Medicines Agency, 2013. Glubrava: procedural steps taken and scientific information after the authorisation 2013 [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000893\/WC500022886.pdf [Accessed 21 August 2013]."},{"key":"2025082722090399000_51.9.105.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2025082722090399000_51.9.105.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2025082722090399000_51.9.105.8","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal Na(+)-glucose transporters","volume":"280","author":"Wright","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025082722090399000_51.9.105.9","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606"},{"key":"2025082722090399000_51.9.105.10","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612"},{"key":"2025082722090399000_51.9.105.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01659.x"},{"key":"2025082722090399000_51.9.105.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"2025082722090399000_51.9.105.13","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-43"},{"key":"2025082722090399000_51.9.105.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"},{"key":"2025082722090399000_51.9.105.15","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"2025082722090399000_51.9.105.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"2025082722090399000_51.9.105.17","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.560181"},{"key":"2025082722090399000_51.9.105.18","doi-asserted-by":"crossref","unstructured":"Clar C . Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2::e001007.","DOI":"10.1136\/bmjopen-2012-001007"},{"key":"2025082722090399000_51.9.105.19","unstructured":"Food and Drug Administration, 2011. FDA briefing document NDA 202293 dapagliflozin tablets, 5 and 10mg. Sponsor: Bristol-Myers Squibb. Advisory committee meeting 19 July 2011 [online]. Available: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM262994.pdf [Accessed 21 August 2013]."},{"key":"2025082722090399000_51.9.105.20","unstructured":"European Medicines Agency, 2012. Assessment report Forxiga [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002322\/WC500136024.pdf [Accessed 21 August 2013]."},{"key":"2025082722090399000_51.9.105.21","unstructured":"National Institute for Health and Care Excellence, 2013. Dapagliflozin in combination therapy for treating type 2 diabetes (TA 288) [online]. Available: http:\/\/publications.nice.org.uk\/dapagliflozin-in-combination-therapy-for-treating-type-2-diabetes-ta288 [Accessed 21 August 2013]."},{"key":"2025082722090399000_51.9.105.22","unstructured":"Scottish Medicines Consortium, 2013. dapagliflozin (Forxiga) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/799_12_dapagliflozin_Forxiga\/dapagliflozin_Forxiga [Accessed 21 August 2013]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2013.9.0205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:09:16Z","timestamp":1756357756000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2013.9.0205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,12]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1136\/dtb.2013.9.0205"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2013.9.0205","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}